FUJIFILM (4901) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
5 Feb, 2026Executive summary
Achieved record highs in Q3 FY2025 for revenue (¥857.4B, +5.5% YoY), operating income (¥90.0B, +2.6% YoY), and net income (¥73.1B, +2.7% YoY), with nine-month revenue at ¥2,429.7B (+4.4% YoY), operating income ¥248.5B (+11.3% YoY), and net income ¥193.4B (+6.5% YoY).
Growth was driven by Healthcare (Bio CDMO), Electronics (semiconductor materials), and Imaging (digital cameras, instant photo systems).
Overseas sales accounted for 66% of nine-month revenue, with notable growth in Europe, the Americas, and Japan.
Despite U.S. tariffs and higher raw material costs, operating income rose due to favorable exchange rates and improved gross margin.
Gross profit margin was 40.9%, with operating margin at 10.2% for the nine-month period.
Financial highlights
Q3 EPS was ¥60.69, up from ¥59.14 YoY; nine-month EPS was ¥160.48, up from ¥150.75 YoY.
Cash and cash equivalents at period end were ¥188.1B, up ¥16.0B from March 2025.
Total assets increased to ¥5,883.1B as of Dec 2025 (+¥633.2B from Mar 2025); shareholders' equity rose by ¥371.8B to ¥3,720.3B.
Adjusted free cash flow (excluding acquisitions) for nine months: −¥164.8B; net cash provided by operating activities was ¥254.3B, with net cash used in investing activities at ¥418.8B.
Overseas sales accounted for 66% of nine-month revenue.
Outlook and guidance
Full-year FY2025 revenue forecast at ¥3,300.0B (unchanged), operating income at ¥335.0B (+1.2%), and net income at ¥264.5B (+1.0%), all record highs.
Annual dividend planned at ¥70/share, marking the 16th consecutive annual increase.
Upward revision in profit forecast driven by strong Electronics and Imaging segments.
Projected exchange rates are ¥150/USD and ¥173/Euro.
Latest events from FUJIFILM
- Record revenue growth, but profits fell due to higher costs and restructuring impacts.4901
Q1 2027 - Record financial results and growth in key segments, with higher dividends and positive outlook.4901
Q4 2026 - IP-driven innovation and portfolio transformation fuel growth in healthcare and electronics.4901
Investor Day 2026 - AI-powered imaging and integrated solutions fuel growth and clinical value in global healthcare.4901
Investor presentation - Aiming for ¥500bn revenue and market leadership in key semiconductor materials by FY2030.4901
Investor Update - Record H1 and Q2 results driven by imaging and bio CDMO growth, with raised revenue guidance.4901
Q2 2026 - Operating income surged 21% on flat revenue, with Imaging leading growth and tariff risks ahead.4901
Q1 2026 - Record Q1 growth and raised outlook driven by electronics and imaging.4901
Q1 2025 - Record revenue and operating income, but net income declined on higher non-operating costs.4901
Q2 2025